Pharmaceutical Sciences Research Centre, Heamoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
J Biomater Sci Polym Ed. 2024 Jan;35(1):63-84. doi: 10.1080/09205063.2023.2268316. Epub 2024 Jan 2.
In the present study, an ionic gelation and ultrasonic approach was performed to produce kojic acid (KA) loaded chitosan(CS)/collagen(CN) nanoparticle(NP) (CSCN-NP) which aimed to increase the dermal delivery and anti-pigmentation effect. To optimize the CSCN-NP the effect of the amount of CN was investigated. The results showed that increasing CN from 0 to 500 mg increased the mean particle size and entrapment efficiency of KA-CSCN-NP from 266.07 ± 9.30 nm to 404.23 ± 9.44 nm and 17.37 ± 2.06% to 82.34 ± 2.16%, respectively. Differential scanning calorimetry confirmed the amorphous form of KA in CSCN-NP, while scanning electron microscopy revealed that the nanoparticles were spherical. There was no chemical interaction between KA and the other components base on attenuated total reflectance-Fourier transform infrared spectroscopy. The skin permeability test showed that KA-CSCN-NP gel delivered more KA to the dermal layers (29.16 ± 1.67% or 537.26 ± 537.26 μg/cm) and receiver compartment (15.04 ± 1.47% or 277.15 ± 27.22 μg/cm) compared to KA plain gel. cytotoxicity assay demonstrated that the improved KA-CSCN-NP was non-toxic. Dermal irritating test on Wistar rats showed that the KA gel was non-irritating. Furthermore, KA-CSCN-NP was found to inhibit melanin formation to a greater extent than free KA and significantly inhibited L-dopa auto-oxidation (94.80 ± 2.41%) compared to pure kojic acid solution (75.28 ± 3.22%). The observations of this study revealed that the produced KA-CSCN-NP might be used as a potential nano-vehicle for KA dermal administration, thereby opening up innovative options for the management of hyper-melanogenesis problems.
在本研究中,采用离子凝胶化和超声法制备了曲酸(KA)负载壳聚糖(CS)/胶原蛋白(CN)纳米粒(CSCN-NP),旨在增加透皮递送和抗色素沉着效果。为了优化 CSCN-NP,考察了 CN 用量的影响。结果表明,随着 CN 从 0 增加到 500mg,KA-CSCN-NP 的平均粒径和包封效率从 266.07±9.30nm 增加到 404.23±9.44nm 和 17.37±2.06%增加到 82.34±2.16%。差示扫描量热法证实 KA 在 CSCN-NP 中呈无定形形式,而扫描电子显微镜显示纳米粒为球形。基于衰减全反射-傅里叶变换红外光谱,KA 与其他成分之间没有化学相互作用。皮肤渗透试验表明,KA-CSCN-NP 凝胶向真皮层(29.16±1.67%或 537.26±537.26μg/cm)和接受室(15.04±1.47%或 277.15±27.22μg/cm)递送更多的 KA。细胞毒性试验表明,改良的 KA-CSCN-NP 无毒性。Wistar 大鼠皮肤刺激性试验表明,KA 凝胶无刺激性。此外,与游离 KA 相比,KA-CSCN-NP 对黑色素形成的抑制作用更大,并显著抑制 L-多巴自动氧化(94.80±2.41%),而与纯曲酸溶液(75.28±3.22%)相比。本研究的观察结果表明,所制备的 KA-CSCN-NP 可用作 KA 经皮给药的潜在纳米载体,为解决黑素生成过度问题提供了新的选择。